Structure-based design of low-nanomolar PIM kinase inhibitors.
Ishchenko, A., Zhang, L., Le Brazidec, J.Y., Fan, J., Chong, J.H., Hingway, A., Raditsis, A., Singh, L., Elenbaas, B., Hong, V.S., Marcotte, D., Silvian, L., Enyedy, I., Chao, J.(2015) Bioorg Med Chem Lett 25: 474-480
- PubMed: 25575657 
- DOI: https://doi.org/10.1016/j.bmcl.2014.12.041
- Primary Citation of Related Structures:  
4X7Q, 4XHK - PubMed Abstract: 
PIM kinases are implicated in variety of cancers by promoting cell survival and proliferation and are targets of interest for therapeutic intervention. We have identified a low-nanomolar pan-PIM inhibitor (PIM1/2/3 potency 5:14:2nM) using structure based modeling. The crystal structure of this compound with PIM1 confirmed the predicted binding mode and protein-ligand interactions except those in the acidic ribose pocket. We show the SAR suggesting the importance of having a hydrogen bond donor in this pocket for inhibiting PIM2; however, this interaction is not important for inhibiting PIM1 or PIM3. In addition, we report the discovery of a new class of PIM inhibitors by using computational de novo design tool implemented in MOE software (Chemical Computing Group). These inhibitors have a different interaction profile.
Organizational Affiliation: 
Biogen Idec, 14 Cambridge Center, Cambridge, MA 02142, USA. Electronic address: al_ishchenko@yahoo.com.